Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Avexis Inc (AVXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 3,193,915
  • Shares Outstanding, K 31,920
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,010 K
  • 36-Month Beta 3.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.42 +13.16%
on 09/26/17
106.00 -5.60%
on 10/13/17
+2.72 (+2.79%)
since 09/20/17
3-Month
82.01 +22.01%
on 07/24/17
106.00 -5.60%
on 10/13/17
+16.97 (+20.42%)
since 07/20/17
52-Week
44.68 +123.95%
on 12/14/16
106.00 -5.60%
on 10/13/17
+55.07 (+122.40%)
since 10/20/16

Most Recent Stories

More News
AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society

- All patients were alive and event-free at 20 months of age as of the August 7, 2017 data cut-off -

AVXS : 100.06 (-0.46%)
Featured Company News - AveXis Intends To Initiate Pivotal Trial Of AVXS-101 In SMA Type 1 On An Immediate Basis

LONDON, UK / ACCESSWIRE / October 3, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AveXis, Inc. (NASDAQ: AVXS), following which we have published...

AVXS : 100.06 (-0.46%)
AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process

- FDA notified AveXis it may initiate pivotal trial based on a review of data provided by the company following CMC Type B meeting -

AVXS : 100.06 (-0.46%)
AveXis Reports Second Quarter 2017 Financial and Operating Results

- AveXis on track to submit potency assay data to FDA in August -

AVXS : 100.06 (-0.46%)
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,111,250 shares of its common stock at a price to the public of $70.00 per share before...

AVXS : 100.06 (-0.46%)
AveXis (AVXS) Jumps: Stock Rises 7.1%

AveXis, Inc.(AVXS) was a big mover last session, as the company saw its shares rise over 7% on the day.

REGN : 432.98 (-1.81%)
AVXS : 100.06 (-0.46%)
AveXis Announces Pricing of Public Offering of Common Stock

AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,575,000 shares of its common stock. The net proceeds to AveXis from the offering, after deducting the underwriting...

AVXS : 100.06 (-0.46%)
AveXis (AVXS) Surges: Stock Moves 5% Higher

AveXis (AVXS) was a big mover last session, as the company saw its shares rise over 5% on the day.

VVUS : 0.80 (unch)
AVXS : 100.06 (-0.46%)
AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector

AveXis, Inc. (NASDAQ:AVXS) and REGENXBIO Inc. (NASDAQ:RGNX) today announced an exclusive worldwide license agreement for AveXis to develop and commercialize gene therapy treatments using REGENXBIO's NAV...

RGNX : 32.75 (+0.92%)
AVXS : 100.06 (-0.46%)
What Falling Estimates & Price Mean for AveXis, Inc. (AVXS)

It seems wise to sell the AveXis, Inc. (AVXS) stock at this moment as its both estimates and price have been witnessing downward revision.

AKTX : 4.54 (+5.09%)
AVXS : 100.06 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant...

See More

Support & Resistance

2nd Resistance Point 103.26
1st Resistance Point 101.66
Last Price 100.06
1st Support Level 98.36
2nd Support Level 96.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart